• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.

作者信息

Gragnano Felice, Natale Francesco, Concilio Claudia, Fimiani Fabio, Cesaro Arturo, Sperlongano Simona, Crisci Mario, Limongelli Giuseppe, Calabrò Raffaele, Russo Mariagiovanna, Golia Enrica, Calabrò Paolo

机构信息

Division of Cardiology, Department of Cardiothoracic and Respiratory Sciences, University of Campania 'Luigi Vanvitelli', A.O. dei Colli Monaldi Hospital, Naples, Italy.

出版信息

J Cardiovasc Med (Hagerstown). 2018 Feb;19(2):75-77. doi: 10.2459/JCM.0000000000000611.

DOI:10.2459/JCM.0000000000000611
PMID:29251697
Abstract
摘要

相似文献

1
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.高心血管风险患者对前蛋白转化酶枯草溶菌素/kexin 9抑制剂的依从性：一项意大利单中心经验。
J Cardiovasc Med (Hagerstown). 2018 Feb;19(2):75-77. doi: 10.2459/JCM.0000000000000611.
2
Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂与他汀类药物降低低密度脂蛋白胆固醇及心血管事件的研究：FOURIER、SPIRE及胆固醇治疗试验协作组分析
Eur Heart J. 2018 Jul 14;39(27):2540-2545. doi: 10.1093/eurheartj/ehx450.
3
[Inhibitors of PCSK9].[前蛋白转化酶枯草溶菌素9抑制剂]
Rev Med Suisse. 2017 Apr 12;13(558):821-825.
4
Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂与心血管风险：对傅里叶试验的进一步分析是否提示降脂治疗靶点的变化？
High Blood Press Cardiovasc Prev. 2018 Mar;25(1):5-7. doi: 10.1007/s40292-017-0244-x. Epub 2018 Jan 5.
5
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）抑制剂。一种用于治疗高胆固醇血症的新型药物类别。
Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):341-344. doi: 10.1016/j.endinu.2017.04.005. Epub 2017 Jun 3.
6
[Up to date lipid lowering treatment].[最新降脂治疗]
Orv Hetil. 2016 Jul;157(31):1219-23. doi: 10.1556/650.2016.30505.
7
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.抑制前蛋白转化酶枯草溶菌素 9（PCSK9）用玻卡鲁胺对高胆固醇血症患者脂蛋白颗粒的影响。
Clin Ther. 2017 Nov;39(11):2243-2259.e5. doi: 10.1016/j.clinthera.2017.09.009. Epub 2017 Oct 14.
8
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.在接受和不接受阿托伐他汀治疗的高胆固醇血症患者中单次和多次给予 bococizumab（一种人源化 IgG2Δa 单克隆抗体，与前蛋白转化酶枯草溶菌素/糜蛋白酶 9 结合）的效果：四项 I 期研究的结果。
Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12309. Epub 2017 Nov 23.
9
Proprotein Convertase Subtilisin Kexin 9 Inhibitors.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂
Cardiol Clin. 2018 May;36(2):241-256. doi: 10.1016/j.ccl.2017.12.006.
10
New Drugs for Lowering LDL-Cholesterol.降低低密度脂蛋白胆固醇的新药。
Rev Med Chir Soc Med Nat Iasi. 2016 Jul-Sep;120(3):485-90.

引用本文的文献

1
Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis.急性冠状动脉综合征患者早期应用前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂：系统评价和荟萃分析。
BMC Cardiovasc Disord. 2024 Jul 30;24(1):395. doi: 10.1186/s12872-024-04057-w.
2
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.替伏西单抗治疗中国非家族性高胆固醇血症患者（CREDIT-1）：一项为期48周的随机、双盲、安慰剂对照3期试验。
Lancet Reg Health West Pac. 2023 Sep 28;41:100907. doi: 10.1016/j.lanwpc.2023.100907. eCollection 2023 Dec.
3
Lipid goal attainment in diabetes mellitus patients after acute coronary syndrome: a subanalysis of Dyslipidemia International Study II-China.
急性冠状动脉综合征后糖尿病患者的血脂达标情况：血脂异常国际研究 II-中国的亚组分析。
BMC Cardiovasc Disord. 2023 Jul 1;23(1):337. doi: 10.1186/s12872-023-03312-w.
4
Effect of bariatric surgery on atherogenicity and insulin resistance in patients with obesity class II: a prospective study.肥胖症 II 级患者行减重手术后对动脉粥样硬化形成及胰岛素抵抗的影响：一项前瞻性研究。
BMJ Open. 2023 Jun 26;13(6):e072418. doi: 10.1136/bmjopen-2023-072418.
5
Distribution of serum uric acid concentration and its association with lipid profiles: a single-center retrospective study in children aged 3 to 12 years with adenoid and tonsillar hypertrophy.血清尿酸浓度分布及其与血脂谱的关系：3-12 岁腺样体和扁桃体肥大儿童的单中心回顾性研究。
Lipids Health Dis. 2023 Apr 6;22(1):48. doi: 10.1186/s12944-023-01806-2.
6
Relation of GRACE Risk Score to Coronary Lipid Core Plaques in Patients with Acute Coronary Syndrome.急性冠脉综合征患者中GRACE风险评分与冠状动脉脂质核心斑块的关系
Life (Basel). 2023 Feb 24;13(3):630. doi: 10.3390/life13030630.
7
LncRNA HIF1A-AS2: a potential biomarker for early diagnosis of acute myocardial infarction and predictor of left ventricular dysfunction.长链非编码 RNA HIF1A-AS2：急性心肌梗死早期诊断的潜在生物标志物和左心室功能障碍的预测因子。
BMC Cardiovasc Disord. 2023 Mar 14;23(1):135. doi: 10.1186/s12872-023-03164-4.
8
In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.急性心肌梗死后院内起始 PCSK9 抑制剂治疗和短期血脂控制。
Lipids Health Dis. 2022 Oct 24;21(1):105. doi: 10.1186/s12944-022-01724-9.
9
Fat-to-muscle ratio as a predictor for dyslipidaemia in transitional-age youth.脂肪-肌肉比预测青春期过渡阶段青年的血脂异常。
Lipids Health Dis. 2022 Sep 19;21(1):88. doi: 10.1186/s12944-022-01697-9.
10
The Impact of the COVID-19 Outbreak on Patients' Adherence to PCSK9 Inhibitors Therapy.2019年冠状病毒病疫情对患者坚持使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂治疗的影响。
J Clin Med. 2022 Jan 18;11(3):475. doi: 10.3390/jcm11030475.